View in Other Languages

Viralytics Limited

ASX:VLA ISIN:AU000000VLA6

Viralytics Limited (ASX:VLA) is engaged in the development of its Virotherapy anti-cancer technology. The Company operates in biotechnology segment.

  

News

Biotech Investors Move Ahead on the Learning Curve

🕔6/11/2015 3:13:43 PM 7194

Australian and New Zealand biotech investors are set to hear from a top line up of speakers from ASX-listed life science companies, as well as several private firms and international businesses, in July, at the 11th Bioshares Biotech Summit.

Read Full Article

Australian Market Report of February 24, 2011: Viralytics (ASX:VLA) Receive Chinese Notice To Grant Patent Of Use Of EVATAK(TM) In Ovarian Cancer

🕔2/24/2011 12:10:55 PM 10062

Australian Market Report of February 24, 2011 includes: Viralytics Limited (ASX:VLA) received a patent granting notice from China regarding the use of EVATAK(TM) as ovarian cancer treatment; Peak Resources Limited (ASX:PEK) reported the remaining assay results from the November-December 2010 RC and diamond drilling campaign; Ferrum Crescent Limited (ASX:FCR) has commenced drilling at the Moonlight Iron Ore Project in South Africa; United Uranium Limited (ASX:UUL) announced that No.1 Institute of Geology and Minerals of Shandong Province received investment approval; Gindalbie Metals Limited (ASX:GBG) announced today that the maiden shipment of iron ore from the Karara Iron Ore Project in Western Australia will occur within two months.

Read Full Article

Australian Market Report of January 31, 2011: Roc Oil (ASX:ROC), Horizon Oil (ASX:HZN), Petsec Energy (ASX:PSA): Joint Venture Achieved Milestone In China Oil Fields Development

🕔1/31/2011 1:30:00 PM 15457

Australian Market Report of January 31, 2011 includes: China National Offshore Oil Company Limited (HKG:0883) (NYSE:CEO) has approved the Project Investment and the Overall Development Plan for the development of the three oil fields in China; Copper Strike Limited (ASX:CSE) signed agreements with China to fund multi-deposit project in North Queensland; Jupiter raises A$150 million to advance mining projects in South Africa and Australia; Viralytics Limited (ASX:VLA) (PINK:VRACY) has received Chinese notice for the grant of a patent involving of the use of CAVATAKTM RNA as an anti-cancer agent in human melanoma.

Read Full Article
###

103,114 COMPANY PROFILE VIEWS

  • This Page Viewed: (Last 7 Days: 53) (Last 30 Days: 213) (Since Published: 9614) 

Markets ASX:VLA

Company Data

    Headquarters
  • McCullough Robertson , Level 11, 66 Eagle Street
    BRISBANE NSW 4001
  • Telephone
  • (02) 9499 3200 
  • Fax
  • (02) 9499 3300 
  • Principal Sector
  • Health & Pharm General 
  • Principal Industry
  • None 
  • Homepage
  • www.viralytics.com

Social Media